T1	intervention 42 71	vinorelbine plus capecitabine
T2	control 79 106	docetaxel plus capecitabine
T4	total-participants 785 787	97
T5	intervention-participants 831 833	55
T6	control-participants 846 848	42
T7	outcome 1116 1139	objective response rate
T8	iv-bin-percent 1141 1146	17.9%
T9	cv-bin-percent 1151 1156	21.1%
T10	outcome 1173 1198	progression-free survival
T11	iv-cont-median 1200 1208	6 months
T12	cv-cont-median 1213 1221	7 months
T13	outcome 1239 1255	overall survival
T14	iv-cont-median 1313 1322	32 months
T15	cv-cont-median 1327 1336	27 months
T16	outcome 1488 1506	hand-foot syndrome
T17	outcome 1436 1447	neutropenia
T18	outcome 1449 1459	leukopenia
T19	outcome 1465 1471	anemia
T3	outcome 1594 1609	adverse effects
T20	outcome 1395 1409	well-tolerated
